ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 607

Activity Index After Renal Failure in a Cohort of 32 Patients with Lupus Nephritis

Cristina Gonzalez-Pulido1, Sara Croca2 and D.A. Isenberg3, 1Internal Medicine, University Hospital Virgen del Rocio, Seville, Spain, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Centre for Rheumatology Research, University College London, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: BILAG, lupus nephritis and transplantation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Most published studies that have measured activity in patients with lupus nephritis suggest the disease is relatively quiescent after renal failure.

Purpose: To analyze retrospectively the activity index of 32 patients in end-renal stage disease (ESRD) from a cohort of 182 patients with lupus nephritis during dialysis and/or post renal transplant. 

Methods: We used the BILAG index, levels of complement C3 (n = 0.9-1.8 g/L) and anti-DNA antibodies (n = 0-50 IU/ml) to measure the lupus activity every 6 months after the beginning of dialysis and after renal transplant. Inactive disease was defined as no BILAG A/B both C3 and DNA level within the normal range. Mild-moderate disease was defined as at least 1 B in BILAG and/or mild serological involvement (C3 levels= 0.89-0.73 g/L and/or DNA levels= 51-149 IU/ml). We considered patients to be severely activity when at least 1 A or 2 B were present in BILAG and/or major serological abnormality (C3 levels< 0.73 g/L and/or DNA levels >149 IU/L). 

Results: We followed up a cohort of 182 patients with lupus nephritis from January 1978 to February 2012. 32 patients went into ESRD defined as the need of haemodialysis (HD) or peritoneal dialysis (CAPD). Ethnically, 37,5% were Afrocaribbean, 25% from the Indian subcontinent, 28% Caucasian and 9,4% others. The duration of follow up during ESRD dialysis ranged from 1 to 144 months (median 24, IQR 12-54). 14 of them had a renal transplant. We divided our cohort in two groups: 1) all patients in ESRD (n=32). 2) Transplant patient (n=14). Group 1: 15.1% of the measurements showed completely inactive disease and 84.9% had at least mild-moderate activity at some time (58.5% had both BILAG index and serological involvement, 26.3% only serological involvement, 16.95% only activity by BILAG. Severely active disease only was present in 54.7% of them (34.2% BILAG and serological, 50% serological, 15.8% only BILAG activity). The BILAG involvement was haematological (29.6%), musculoskeletal (19.7%), mucocutaneous (15.5%), constitutional (11.3%), neurological (8.4%) and gastrointestinal (1.4%). 12 patients died. Group 2: 42.3% of the measurements showed inactive disease and 57.7% had at least one flare in this period (43.3% BILAG and serological, 23.3% serologically, 33,3% by BILAG). Severe activity markers were present in only 26.92% (50% BILAG and serological, 32,14% BILAG, 17.9% serologically). The BILAG involvement in this group was due to renal alteration (34%), haematological (30%), constitutional (10%), neurological and cardiovascular (8% each), mucocutaneous (6%), musculoskeletal and gastrointestinal (2%) each. 2 patients died.

Conclusion: We report a 34 years follow-up of a cohort of 32 patients with SLE nephritis in renal failure. The activity after ESRD was much lower in the group of transplant patients. Serological activity was the main finding in both groups.


Disclosure:

C. Gonzalez-Pulido,
None;

S. Croca,
None;

D. A. Isenberg,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/activity-index-after-renal-failure-in-a-cohort-of-32-patients-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology